Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | JAVELIN Bladder 100: practice-changing data

Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, outlines the findings from the JAVELIN Bladder 100 study (NCT02603432), a Phase III randomized trial of maintenance avelumab in advanced urothelial cancer patients who have not progressed with first-line platinum-based chemotherapy. Additionally, Dr Plimack highlights the practice-changing implications of these data. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.